Pharmaceuticals, Biotechnology and Life Sciences
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#Eyevensys–Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program …
DUBLIN–(BUSINESS WIRE)–The “Drugs For Erectile Dysfunction Global Market Report 2020-30: COVID-19 Impact and Recovery” report has been added to ResearchAndMarkets.com’s offering.
The global drugs for erectile dysfunction market is expected to declin…
DUBLIN–(BUSINESS WIRE)–The “Asia-Pacific Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarke…
DUBLIN–(BUSINESS WIRE)–The “Europe Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com…
DUBLIN–(BUSINESS WIRE)–The “North America Pharmaceutical Contract Research Organization (CRO) Market 2020-2030 by Service, Therapeutic Application, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMark…
DUBLIN–(BUSINESS WIRE)–The “US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.
US Prostate Cancer Drug Market, Drug Price, Dosage & Clinical Trials I…
Evidence of positive biological response to LYS-SAF302 in patients treated in the AAVance clinical trial
~30% decrease in pathological heparan sulfate in cerebrospinal fluid 12 months after treatment
~40% decrease in pathological GM2 and GM3 gan…
Early demonstration of favorable LUMEVOQ® safety profile in human subjects subsequently confirmed in later trials
Dose for Phase III trials selected based on best benefit-risk ratio demonstrated across four cohorts
Favorable safety and tolerabili…
Conference Call Scheduled for Monday, February 22, 2021 at 4:30 p.m. ET. NEWARK, Calif.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a…
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative…